Brian Cordery

by Steven Willis and Olivia Henry On 28 March 2018, the Court of Appeal overturned Henry Carr J’s finding that two Regeneron patents (EP (UK) 1 360 287 and EP (UK) 2 264 163) were insufficient. The…

Around this time last year, in Edwards Lifesciences v Boston Scientific [2017], His Honour Judge Hacon (sitting as a High Court Judge) had the opportunity to analyse two interesting aspects of UK…

There has been much excitement and comment amongst the UK patent profession following the Supreme Court’s decision in Actavis v Eli Lilly [2017] UKSC 48 (see previous comment here) on patent claim…

Whilst many in show business have long lived by the adage “never work with children or animals” for fear of what might ensue, patent litigators in the UK have long been known to take a similar…

Few would dispute that the Actavis v Eli Lilly decision from the Supreme Court in July 2017 represented - for better or for worse - a major change to the scope of protection of patents in the UK…

By Gregory Bacon Yes, you read that right. Thirteen years after the House of Lords had firmly shut the door on any notion of a doctrine extending the scope of patent protection outside the claims,…

By Gregory Bacon The UK Supreme Court announced this morning that it has allowed Eli Lilly's appeal and held that Actavis' pemetrexed products directly infringe Lilly's European patent to pemetrexed…

The sunrise session of day 2 was on second medical use claims and the hot European topic of plausibility. Floyd LJ began with a potted history and explained that whereas plausibility can be raised in…

The Fordham IP Conference in New York is celebrating its 25th anniversary this year. As the conference heads into its second quarter-century, the programme and faculty are as impressive as ever. …